drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Long-acting broadly neutralizing anti–HIV-1 human IgG1 monoclonal antibody with LS Fc mutations for extended half-life; targets the gp120 V3 glycan (N332) supersite to neutralize virus and block entry, and engages Fcγ receptor–mediated effector functions (ADCC, phagocytosis) to eliminate Env-expressing infected cells and reduce the intact proviral reservoir.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
A long-acting broadly neutralizing human IgG1 monoclonal antibody with LS Fc mutations that extend half-life; it binds the HIV-1 Env gp120 V3 glycan (N332) supersite to neutralize virions and block viral entry, and engages Fcγ receptors to mediate ADCC and phagocytosis of Env-expressing infected cells, aiming to reduce the intact proviral reservoir.
drug_name
10-1074-LS
nct_id_drug_ref
NCT05612178